SENSORCAINE WITH EPINEPHRINE SOLUTION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

EPINEPHRINE (EPINEPHRINE BITARTRATE); BUPIVACAINE HYDROCHLORIDE

Available from:

ASPEN PHARMACARE CANADA INC.

ATC code:

N01BB51

INN (International Name):

BUPIVACAINE, COMBINATIONS

Dosage:

5MCG; 2.5MG

Pharmaceutical form:

SOLUTION

Composition:

EPINEPHRINE (EPINEPHRINE BITARTRATE) 5MCG; BUPIVACAINE HYDROCHLORIDE 2.5MG

Administration route:

BLOCK/INFILTRATION

Units in package:

20ML

Prescription type:

Ethical

Therapeutic area:

LOCAL ANESTHETICS

Product summary:

Active ingredient group (AIG) number: 0204884001; AHFS:

Authorization status:

APPROVED

Authorization date:

2000-02-14

Summary of Product characteristics

_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
SENSORCAINE
®
Bupivacaine Hydrochloride
Solution, 0.25% (2.5 mg/mL) and 0.5% (5 mg/mL), Epidural,
Block/Infiltration
USP
SENSORCAINE
® WITH EPINEPHRINE
Bupivacaine Hydrochloride and Epinephrine
Solution, 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine
bitartrate [(1:200,000) 5 mcg/mL]
and 0.5% bupivacaine hydrochloride (5 mg/mL) and epinephrine
bitartrate [(1:200,000) 5 mcg/mL], Epidural, Block/Infiltration
USP
Local Anesthetics
Aspen Pharmacare Canada Inc
8-1155 North Service Road West Oakville,
Ontario, L6M 3E3
Date of Initial Authorization:
MAR 02, 2000
Date of Revision: April 12,
2022
Submission Control Number: 254303
Trademarks are owned by or licensed to the Aspen Group of companies.
© 2022 ASPEN GROUP OF COMPANIES OR ITS LICENSOR. ALL RIGHTS RESERVED.
_<_
_SENSORCAINE_
_®_
_>< Bupivacaine Hydrochloride > Page 2 of 36 _
_<_
_SENSORCAINE_
_®_
_ with Epinephrine> _
_ _
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions
04/2021
7.Warnings and Precautions, hepatic
04/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics
....................................................................................................................4
1.2
Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS
........................................